Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZK2503
- Development stage
- Preclinical
- Lead developer
- Lee's Pharmaceutical
- Modality
- Small Molecules
01
Overview
ZK2503 is a small molecule pan-cyclin-dependent kinase (CDK) inhibitor currently in preclinical development by Lee's Pharmaceutical for the treatment of solid tumors. Originally developed by Schering AG (now Bayer) and licensed to Lee's Pharmaceutical, ZK2503 is designed to inhibit multiple CDK isoforms, including CDK1, CDK2, CDK4, CDK7, and CDK9. These kinases are essential regulators of the cell cycle and gene transcription, and their dysregulation is a hallmark of many cancers. By blocking these targets, ZK2503 aims to induce cell cycle arrest and apoptosis, thereby inhibiting tumor growth. The compound is being evaluated for its potential as a targeted therapy in various solid tumor indications.
- Other names
- pan-CDK inhibitor ZK2503
02
Targets
CDK7CDK4 (Cyclin-dependent kinase 4)CDK9 (Cyclin-dependent kinase 9)CDK2 (Cyclin-dependent kinase 2)CDK1 (Cyclin-dependent kinase 1)
Beyond the preview
Go deeper on ZK2503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZK2503.